Researchers analyzed data from 108,647 postmenopausal women diagnosed with breast cancer to see if there was an increased risk of the disease for those who used menopausal hormone therapy.
In 2017, about half of physician directors at National Cancer Institute cancer centers received payments related to research, while a quarter received payments over $5,000 that were not related to research.
Researchers suggested that the reduction of drug spending by using value-based clinical pathways to optimize chemotherapy utilization is possible and can increase the chances of a practice’s success within the Oncology Care Model.
These projections suggest that premature and sudden lifting of interventions put in place could lead to an earlier secondary peak of COVID-19, which could be flattened by relaxing the interventions gradually.
Researchers reported on the incidence and outcomes of the SARS-CoV-2 infection, which has been linked to COVID-19, in patients with cancer who were treated at a tertiary cancer institution in Wuhan, China.
A study with a small sample size revealed that trastuzumab deruxtecan showed promising activity in multiple HER2-expressing or HER2-mutant solid tumors.
Favorable toxicity profiles and antitumor activity seen in this phase II study of pembrolizumab supports further evaluation of the drug in this patient population.
The European Society for Medical Oncology released key answers to questions about the coronavirus disease 2019 (COVID-19) as it pertains to cancer care.
The FDA has approved a phase III clinical trial to assess the safety and efficacy of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.
In this study, polypharmacy during the 6-month time period pre-IV chemotherapy was highly predictive of post-chemotherapy inpatient hospitalization.